 While reporting financial results for the second fiscal quarter of the year, during which revenues grew more than 15 to 4.9 billion, Becton Dickinson and Co NYSE: BDX also laid out its plans to spin off its diabetes-focused segment. Split Highlights: The split is expected to be completed in the first half of 2022, after which the segment will become a completely separate, publicly-traded company, tentatively dubbed NewCo. 